GW280264X

Cas：866924-39-2

Product Information：

GW280264X is an ADAM17 inhibitor.

Chemical Formula: C28H41N5O6S

Exact Mass: 575.2778

Molecular Weight: 575.725

Elemental Analysis: C, 58.41; H, 7.18; N, 12.16; O, 16.67; S, 5.57

Synonym:

GW280264X

GW-280264X

GW 280264X

GW280264

GW-280264

GW 280264

Chemical Name:

BenzylN-[(5S)-5-[[(2R,3S)-3-(Formylhydroxyamino)-2-(2-methylpropyl)-1-oxohexyl]amino]-6-oxo-6-(2-thiazolylamino)hexyl]-carbamate

InChi Key:

SKJLITFHSZNZMQ-SGNDLWITSA-N

InChi Code: InChI=1S/C28H41N5O6S/c1-4-10-24(33(38)19-34)22(17-20(2)3)25(35)31-23(26(36)32-27-29-15-16-40-27)13-8-9-14-30-28(37)39-18-21-11-6-5-7-12-21/h5-7,11-12,15-16,19-20,22-24,38H,4,8-10,13-14,17-18H2,1-3H3,(H,30,37)(H,31,35)(H,29,32,36)/t22-,23+,24+/m1/s1

Smiles Code:

O=C(OCC1=CC=CC=C1)NCCCC[C@H](NC([C@H](CC(C)C)[C@@H](N(C=O)O)CCC)=O)C(NC2=NC=CS2)=O

Technical Data：

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

References：

1. Yang J, LeBlanc ME, Cano I, Saez-Torres KL, Saint-Geniez M, Ng YS, D'Amore PA. ADAM10 and ADAM17 proteases mediate proinflammatory cytokine-induced and constitutive cleavage of endomucin from the endothelial surface. J Biol Chem. 2020 May 8;295(19):6641-6651. doi: 10.1074/jbc.RA119.011192. Epub 2020 Mar 19. PMID: 32193206; PMCID: PMC7212652.

2. Kouam PN, Rezniczek GA, Adamietz IA, Bühler H. Ionizing radiation increases the endothelial permeability and the transendothelial migration of tumor cells through ADAM10-activation and subsequent degradation of VE-cadherin. BMC Cancer. 2019 Oct 16;19(1):958. doi: 10.1186/s12885-019-6219-7. PMID: 31619190; PMCID: PMC6794838.

3. Saad MI, McLeod L, Yu L, Ebi H, Ruwanpura S, Sagi I, Rose-John S, Jenkins BJ. The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis. Carcinogenesis. 2020 Jun 17;41(4):527-538. doi: 10.1093/carcin/bgz123. PMID: 31257400.

4. Malemud CJ. Inhibition of MMPs and ADAM/ADAMTS. Biochem Pharmacol. 2019 Jul;165:33-40. doi: 10.1016/j.bcp.2019.02.033. Epub 2019 Feb 28. PMID: 30826330; PMCID: PMC6557692.

5. Hedemann N, Rogmans C, Sebens S, Wesch D, Reichert M, Schmidt-Arras D, Oberg HH, Pecks U, van Mackelenbergh M, Weimer J, Arnold N, Maass N, Bauerschlag DO. ADAM17 inhibition enhances platinum efficiency in ovarian cancer. Oncotarget. 2018 Mar 23;9(22):16043-16058. doi: 10.18632/oncotarget.24682. PMID: 29662625; PMCID: PMC5882316.

Products are for research use only. Not for human use.